Prime Medicine is exploding higher today following the company's announcement on October 5 that it has dosed the first patient in its Phase 1/2 clinical trial for PM577a, an in vivo Prime Editor therapy for H1069Q-mutated Wilson disease. This clinical milestone, which was bolstered by the FDA granting the program Rare Pediatric Disease designation, serves as the primary catalyst for the stock's upward momentum. The move is further supported by positive sentiment in the broader biotechnology sector, as evidenced by gains in peers such as CRISPR Therapeutics and Beam Therapeutics.